Trial · NCT04026113
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind Treatment Period (12 Weeks) | STARTED | FC Participants: Placebo | 164 | |
| Double-Blind Treatment Period (12 Weeks) | STARTED | FC Participants: Linaclotide 72 μg | 166 | |
| Double-Blind Treatment Period (12 Weeks) | STARTED | IBS-C Participants: Linaclotide 145 μg | 55 | |
| Double-Blind Treatment Period (12 Weeks) | STARTED | IBS-C Participants: Linaclotide 290 μg | 53 | |
| Double-Blind Treatment Period (12 Weeks) | Randomized and Treated | FC Participants: Placebo | 164 | |
| Double-Blind Treatment Period (12 Weeks) | Randomized and Treated | FC Participants: Linaclotide 72 μg | 164 | |
| Double-Blind Treatment Period (12 Weeks) | Randomized and Treated | IBS-C Participants: Linaclotide 145 μg | 55 | |
| Double-Blind Treatment Period (12 Weeks) | Randomized and Treated | IBS-C Participants: Linaclotide 290 μg | 53 | |
| Double-Blind Treatment Period (12 Weeks) | COMPLETED | FC Participants: Placebo | 145 | |
| Double-Blind Treatment Period (12 Weeks) | COMPLETED | FC Participants: Linaclotide 72 μg | 148 | |
| Double-Blind Treatment Period (12 Weeks) | COMPLETED | IBS-C Participants: Linaclotide 145 μg | 52 | |
| Double-Blind Treatment Period (12 Weeks) | COMPLETED | IBS-C Participants: Linaclotide 290 μg | 46 | |
| Double-Blind Treatment Period (12 Weeks) | NOT COMPLETED | FC Participants: Placebo | 19 | |
| Double-Blind Treatment Period (12 Weeks) | NOT COMPLETED | FC Participants: Linaclotide 72 μg | 18 | |
| Double-Blind Treatment Period (12 Weeks) | NOT COMPLETED | IBS-C Participants: Linaclotide 145 μg | 3 | |
| Double-Blind Treatment Period (12 Weeks) | NOT COMPLETED | IBS-C Participants: Linaclotide 290 μg | 7 | |
| Post-Intervention Period (1 Week) | STARTED | FC Participants: Placebo | 66 | |
| Post-Intervention Period (1 Week) | STARTED | FC Participants: Linaclotide 72 μg | 75 | |
| Post-Intervention Period (1 Week) | STARTED | IBS-C Participants: Linaclotide 145 μg | 20 | |
| Post-Intervention Period (1 Week) | STARTED | IBS-C Participants: Linaclotide 290 μg | 20 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04026113/flow